Malgorzata Mikulska, Monica Melchio, Alessio Signori, Nadir Ullah, Franca Miletich, Chiara Sepulcri, Alessandro Limongelli, Daniele Roberto Giacobbe, Elisa Balletto, Chiara Russo, Laura Magnasco, Antonio Vena, Carmen Di Grazia, Anna Maria Raiola, Federica Portunato, Chiara Dentone, Denise Battaglini, Lorenzo Ball, Chiara Robba, Emanuele Angelucci, Iole Brunetti, Matteo Bassetti
BACKGROUND: Isavuconazole is first-line treatment of invasive aspergillosis. Therapeutic drug monitoring (TDM) is deemed not necessary, since most patients reached therapeutic levels (>1 mg/L) in large studies. Low levels were reported in some critically ill patients admitted to the ICU. The aim was to compare isavuconazole levels between critically ill and non-critically ill patients. MATERIALS AND METHODS: Retrospective analysis of data from all patients treated with standard-dose isavuconazole between 1 January 2019 and 26 October 2022 was performed...
February 15, 2024: Journal of Antimicrobial Chemotherapy